{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T13:32:10Z","timestamp":1784381530421,"version":"3.55.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100010795","name":"Chugai Pharmaceutical Co., Ltd.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100010795","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ophthal Inflamm Infect"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>Non-infectious uveitis (NIU) can arise from various inflammatory disorders and can cause vision loss. Patients with mild NIU are typically treated with corticosteroid eye drops to reduce intraocular inflammation; however, other local\/systemic treatments (corticosteroids, immunosuppressants, biologics) may be required for moderate-to-severe NIU, which may cause ocular complications. Here, we investigated real-world treatment patterns for NIU in Japan.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Patients were selected from a large, Japanese insurance claims database using <jats:italic>International Classification of Diseases<\/jats:italic>,<jats:italic> Tenth Revision<\/jats:italic> codes; diagnosis of NIU was confirmed via ophthalmological examination (October 2016\u2013October 2023). Sankey diagrams were used to describe treatment transitions. Post-treatment ocular complications, potentially related surgeries, and fundus findings associated with uveitis were determined.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The majority of patients (68.7%; 37,869\/55,091) were treated with corticosteroid eye drops only for mild NIU; 19.0% (10,449\/55,091) were given other treatments for moderate-to-severe NIU, mostly oral corticosteroids (7,473\/10,449) and posterior sub-Tenon\u2019s corticosteroid injections (1,636\/10,449). In patients treated with corticosteroids orally or via sub-Tenon\u2019s injections, common transitions were to corticosteroid eye drops or censor (end of treatment\/dataset or insurance withdrawal). A higher incidence of treatment-related ocular complications and potentially related surgeries (including glaucoma) was observed during the first year of NIU treatment compared with subsequent years (for moderate-to-severe NIU, estimated incidence of prescription of glaucoma drugs was 106 per 1,000 person-years [at 1 year], 73 per 1,000 person-years [at 2 years], and 52 per 1,000 person-years [at 5 years]).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Our comprehensive analysis of a large claims database included all prescribed medications and medical procedures (including local injections) for NIU treatment in Japan up to October 2023. Although corticosteroids are a mainstay of NIU treatment in Japan, we found that a number of treatments for moderate-to-severe NIU, other than corticosteroid eye drops, are frequently used in combination with or when switching from corticosteroid eye drops. These findings are of importance when assessing the treatment landscape and may help identify unmet clinical needs in patients with NIU.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12348-025-00514-5","type":"journal-article","created":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T03:55:46Z","timestamp":1753156546000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Real-world treatment patterns for patients with non-infectious uveitis in Japan: a descriptive study using a large-scale claims database (J-CAT study)"],"prefix":"10.1186","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6458-539X","authenticated-orcid":false,"given":"Sentaro","family":"Kusuhara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9819-5509","authenticated-orcid":false,"given":"Koh-Hei","family":"Sonoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1132-6148","authenticated-orcid":false,"given":"Toshikatsu","family":"Kaburaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tachie","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saki","family":"Katayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misako","family":"Makishima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takao","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5702-0121","authenticated-orcid":false,"given":"Mariko","family":"Nio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2120-6839","authenticated-orcid":false,"given":"Takashi","family":"Omoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukari","family":"Matsuo-Tezuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoki","family":"Yoshizaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensuke","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kairi","family":"Ri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3302-022X","authenticated-orcid":false,"given":"Keiko","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,22]]},"reference":[{"key":"514_CR1","doi-asserted-by":"publisher","first-page":"640473","DOI":"10.3389\/fimmu.2021.640473","volume":"12","author":"M Takeuchi","year":"2021","unstructured":"Takeuchi M, Mizuki N, Ohno S (2021) Pathogenesis of non-infectious uveitis elucidated by recent genetic findings. Front Immunol 12:640473","journal-title":"Front Immunol"},{"issue":"2","key":"514_CR2","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1007\/s10384-020-00809-1","volume":"65","author":"KH Sonoda","year":"2021","unstructured":"Sonoda KH, Hasegawa E, Namba K, Okada AA, Ohguro N, Goto H (2021) Epidemiology of uveitis in japan: a 2016 retrospective nationwide survey. Jpn J Ophthalmol 65(2):184\u2013190","journal-title":"Jpn J Ophthalmol"},{"issue":"1","key":"514_CR3","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/s41433-018-0223-z","volume":"33","author":"YR Hsu","year":"2019","unstructured":"Hsu YR, Huang JC, Tao Y et al (2019) Noninfectious uveitis in the Asia-Pacific region. Eye (Lond) 33(1):66\u201377","journal-title":"Eye (Lond)"},{"key":"514_CR4","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ajo.2019.06.005","volume":"208","author":"KM Niemeyer","year":"2019","unstructured":"Niemeyer KM, Gonzales JA, Doan T, Browne EN, Rao MM, Acharya NR (2019) Time trade-off utility values in noninfectious uveitis. Am J Ophthalmol 208:47\u201355","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"514_CR5","doi-asserted-by":"publisher","first-page":"e000896","DOI":"10.1136\/bmjophth-2021-000896","volume":"6","author":"SM Hariprasad","year":"2021","unstructured":"Hariprasad SM, Joseph G, Gagnon-Sanschagrin P et al (2021) Healthcare costs among patients with macular oedema associated with non-infectious uveitis: a US commercial payer\u2019s perspective. BMJ Open Ophthalmol 6(1):e000896","journal-title":"BMJ Open Ophthalmol"},{"issue":"3","key":"514_CR6","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1080\/25785826.2019.1678961","volume":"42","author":"K Maruyama","year":"2019","unstructured":"Maruyama K (2019) Current standardized therapeutic approach for uveitis in Japan. Immunol Med 42(3):124\u2013134","journal-title":"Immunol Med"},{"issue":"4","key":"514_CR7","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1007\/s10238-022-00954-6","volume":"23","author":"X Wu","year":"2023","unstructured":"Wu X, Tao M, Zhu L, Zhang T, Zhang M (2023) Pathogenesis and current therapies for non-infectious uveitis. Clin Exp Med 23(4):1089\u20131106","journal-title":"Clin Exp Med"},{"issue":"2","key":"514_CR8","first-page":"CD010469","volume":"2","author":"CJ Brady","year":"2016","unstructured":"Brady CJ, Villanti AC, Law HA et al (2016) Corticosteroid implants for chronic non-infectious uveitis. Cochrane Database Syst Rev 2(2):CD010469","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"514_CR9","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.ophtha.2017.11.017","volume":"125","author":"AD Dick","year":"2018","unstructured":"Dick AD, Rosenbaum JT, Al-Dhibi HA et al (2018) Guidance on noncorticosteroid systemic immunomodulatory therapy in noninfectious uveitis: fundamentals of care for uveitis (FOCUS) initiative. Ophthalmology 125(5):757\u2013773","journal-title":"Ophthalmology"},{"issue":"6","key":"514_CR10","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.survophthal.2015.06.004","volume":"60","author":"M Cordero-Coma","year":"2015","unstructured":"Cordero-Coma M, Sobrin L (2015) Anti\u2013tumor necrosis factor-\u03b1 therapy in uveitis. Surv Ophthalmol 60(6):575\u2013589","journal-title":"Surv Ophthalmol"},{"issue":"1","key":"514_CR11","doi-asserted-by":"publisher","first-page":"22227","DOI":"10.1038\/s41598-020-78718-z","volume":"10","author":"N Horiguchi","year":"2020","unstructured":"Horiguchi N, Kamoi K, Horie S et al (2020) A 10-year follow-up of Infliximab monotherapy for refractory uveitis in Beh\u00e7et\u2019s syndrome. Sci Rep 10(1):22227","journal-title":"Sci Rep"},{"key":"514_CR12","doi-asserted-by":"publisher","first-page":"1412930","DOI":"10.3389\/fopht.2024.1412930","volume":"4","author":"K Chauhan","year":"2024","unstructured":"Chauhan K, Tyagi M (2024) Update on non-infectious uveitis treatment: anti-TNF-alpha and beyond. Front Ophthalmol 4:1412930","journal-title":"Front Ophthalmol"},{"key":"514_CR13","doi-asserted-by":"publisher","unstructured":"Garweg JG, Straessle KA (2024) Janus kinase inhibitors as a third-line therapy for refractory endogenous noninfectious uveitis. Ocul Immunol Inflamm 1\u20138. https:\/\/doi.org\/10.1080\/09273948.2024.2348125","DOI":"10.1080\/09273948.2024.2348125"},{"issue":"3","key":"514_CR14","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.ophtha.2015.10.028","volume":"123","author":"AD Dick","year":"2016","unstructured":"Dick AD, Tundia N, Sorg R et al (2016) Risk of ocular complications in patients with noninfectious intermediate uveitis, posterior uveitis, or panuveitis. Ophthalmology 123(3):655\u2013662","journal-title":"Ophthalmology"},{"issue":"6","key":"514_CR15","doi-asserted-by":"publisher","first-page":"277","DOI":"10.4103\/0301-4738.114099","volume":"61","author":"K Babu","year":"2013","unstructured":"Babu K, Mahendradas P (2013) Medical management of uveitis - current trends. Indian J Ophthalmol 61(6):277\u2013283","journal-title":"Indian J Ophthalmol"},{"key":"514_CR16","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.2147\/OPTH.S273938","volume":"14","author":"N Takai","year":"2020","unstructured":"Takai N, Kobayashi T, Kida T, Ikeda T (2020) Clinical features of Japanese patients with ocular inflammation and their surgical procedures over the course of 20 years. Clin Ophthalmol 14:2799\u20132806","journal-title":"Clin Ophthalmol"},{"issue":"9","key":"514_CR17","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.4103\/ijo.IJO_1548_20","volume":"68","author":"H Agrawal","year":"2020","unstructured":"Agrawal H, Doan H, Pham B et al (2020) Systemic immunosuppressive therapies for uveitis in developing countries. Indian J Ophthalmol 68(9):1852\u20131862","journal-title":"Indian J Ophthalmol"},{"issue":"2","key":"514_CR18","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1001\/jamaophthalmol.2022.5584","volume":"141","author":"S Bellur","year":"2023","unstructured":"Bellur S, McHarg M, Kongwattananon W, Vitale S, Sen HN, Kodati S (2023) Antidrug antibodies to tumor necrosis factor \u03b1 inhibitors in patients with noninfectious uveitis. JAMA Ophthalmol 141(2):150\u2013156","journal-title":"JAMA Ophthalmol"},{"issue":"1","key":"514_CR19","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12348-020-00202-6","volume":"10","author":"F Nicolela Susanna","year":"2020","unstructured":"Nicolela Susanna F, Pavesio C (2020) A review of ocular adverse events of biological anti-TNF drugs. J Ophthalmic Inflamm Infect 10(1):11","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"514_CR20","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.jare.2018.09.003","volume":"15","author":"L Quartuccio","year":"2019","unstructured":"Quartuccio L, Zabotti A, Del Zotto S, Zanier L, De Vita S, Valent F (2019) Risk of serious infection among patients receiving biologics for chronic inflammatory diseases: usefulness of administrative data. J Adv Res 15:87\u201393","journal-title":"J Adv Res"},{"issue":"9","key":"514_CR21","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1001\/jamadermatol.2021.2599","volume":"157","author":"L Penso","year":"2021","unstructured":"Penso L, Dray-Spira R, Weill A, Pina Vegas L, Zureik M, Sbidian E (2021) Association between biologics use and risk of serious infection in patients with psoriasis. JAMA Dermatol 157(9):1056\u20131065","journal-title":"JAMA Dermatol"},{"issue":"5","key":"514_CR22","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1007\/s10384-021-00850-8","volume":"65","author":"A Umazume","year":"2021","unstructured":"Umazume A, Ohguro N, Okada AA et al (2021) Prevalence and incidence rates and treatment patterns of non-infectious uveitis in Japan: real-world data using a claims database. Jpn J Ophthalmol 65(5):657\u2013665","journal-title":"Japan J Ophthalmol"},{"issue":"4","key":"514_CR23","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1007\/s10384-022-00923-2","volume":"66","author":"A Umazume","year":"2022","unstructured":"Umazume A, Ohguro N, Okada AA et al (2022) Use of systemic corticosteroids in patients newly registered at a claims database with a diagnosis of non-infectious uveitis: results from a real-world claims database analysis. Jpn J Ophthalmol 66(4):394\u2013404","journal-title":"Jpn J Ophthalmol"},{"issue":"3","key":"514_CR24","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1002\/jgf2.422","volume":"22","author":"K Nagai","year":"2021","unstructured":"Nagai K, Tanaka T, Kodaira N, Kimura S, Takahashi Y, Nakayama T (2021) Data resource profile: JMDC claims database sourced from health insurance societies. J Gen Fam Med 22(3):118\u2013127","journal-title":"J Gen Fam Med"},{"key":"514_CR25","doi-asserted-by":"crossref","unstructured":"Laurent T, Simeone J, Kuwatsuru R, et al (2022) Context and considerations for use of two Japanese real-world databases in Japan: medical data vision and Japanese Medical Data Center. Drugs Real World Outcomes 9(2):175\u2013187","DOI":"10.1007\/s40801-022-00296-5"},{"issue":"3","key":"514_CR26","first-page":"462","volume":"26","author":"N Khan","year":"2019","unstructured":"Khan N, Vallarino C, Lissoos T, Darr U, Luo M (2019) Risk of infection and types of infection among elderly patients with inflammatory bowel disease: a retrospective database analysis. Inflamm Bowel Dis 26(3):462\u2013468","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"514_CR27","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1186\/s12879-023-08466-8","volume":"23","author":"R Hase","year":"2023","unstructured":"Hase R, Suzuki D, de Luise C et al (2023) Validity of claims-based diagnoses for infectious diseases common among immunocompromised patients in Japan. BMC Infect Dis 23(1):653","journal-title":"BMC Infect Dis"},{"issue":"7","key":"514_CR28","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1111\/bcp.15687","volume":"89","author":"R Ota","year":"2023","unstructured":"Ota R, Hata T, Hirata A et al (2023) Risk of infection from glucocorticoid and methotrexate interaction in patients with rheumatoid arthritis using biologics: a retrospective cohort study. Br J Clin Pharmacol 89(7):2168\u20132178","journal-title":"Br J Clin Pharmacol"},{"key":"514_CR29","doi-asserted-by":"publisher","unstructured":"Liba T, Alon G, Liron L, Raz G, Elcio M, and Segal O (2025) Epidemiological characterization of uveitis in Japan: a systematic review. Ocul Immunol Inflamm 1\u201310. https:\/\/doi.org\/10.1080\/09273948.2025.2452193","DOI":"10.1080\/09273948.2025.2452193"},{"issue":"11","key":"514_CR30","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.1016\/j.clinthera.2017.09.011","volume":"39","author":"JB Rice","year":"2017","unstructured":"Rice JB, White AG, Scarpati LM, Wan G, Nelson WW (2017) Long-term systemic corticosteroid exposure: a systematic literature review. Clin Ther 39(11):2216\u20132229","journal-title":"Clin Ther"},{"key":"514_CR31","volume-title":"Corticosteroid adverse effects","author":"M Yasir","year":"2024","unstructured":"Yasir M, Goyal A, Sonthalia S (2024) Corticosteroid adverse effects. StatPearls Publishing, Treasure Island"},{"key":"514_CR32","doi-asserted-by":"crossref","unstructured":"Kirupaharan N, Marshall RF, Spangler MD, Armbrust KR, Berkenstock MK (2025) Incidence and Prevalence of uveitis and associated ocular complications in the United States TriNetX Database. Am J Ophthalmol 276;30-39","DOI":"10.1016\/j.ajo.2025.03.032"},{"issue":"3","key":"514_CR33","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1111\/ceo.13702","volume":"48","author":"AT Fung","year":"2020","unstructured":"Fung AT, Tran T, Lim LL et al (2020) Local delivery of corticosteroids in clinical ophthalmology: a review. Clin Exp Ophthalmol 48(3):366\u2013401","journal-title":"Clin Exp Ophthalmol"},{"issue":"9","key":"514_CR34","doi-asserted-by":"publisher","first-page":"e14668","DOI":"10.1097\/MD.0000000000014668","volume":"98","author":"M Takeuchi","year":"2019","unstructured":"Takeuchi M, Kanda T, Kaburaki T et al (2019) Real-world evidence of treatment for relapse of noninfectious uveitis in tertiary centers in Japan: a multicenter study. Medicine 98(9):e14668","journal-title":"Medicine"},{"issue":"1","key":"514_CR35","doi-asserted-by":"publisher","first-page":"2352019","DOI":"10.1080\/07853890.2024.2352019","volume":"56","author":"YC Chang","year":"2024","unstructured":"Chang YC, Kao TE, Chen CL et al (2024) Use of corticosteroids in non-infectious uveitis - expert consensus in Taiwan. Ann Med 56(1):2352019","journal-title":"Ann Med"},{"issue":"1","key":"514_CR36","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12348-021-00281-z","volume":"12","author":"M McHarg","year":"2022","unstructured":"McHarg M, Young L, Kesav N, Yakin M, Sen HN, Kodati S (2022) Practice patterns regarding regional corticosteroid treatment in noninfectious uveitis: a survey study. J Ophthalmic Inflamm Infect 12(1):3","journal-title":"J Ophthalmic Inflamm Infect"},{"issue":"6","key":"514_CR37","first-page":"635","volume":"123","author":"Committee for the Creation of Clinical Guidelines for Uveitis, Japan Society of Ocular Inflammation","year":"2019","unstructured":"Committee for the Creation of Clinical Guidelines for Uveitis, Japan Society of Ocular Inflammation (2019) Uveitis management guidelines. Nippon Ganka Gakkai Zasshi 123(6):635\u2013696","journal-title":"Nippon Ganka Gakkai Zasshi"},{"key":"514_CR38","doi-asserted-by":"publisher","first-page":"740057","DOI":"10.3389\/fphar.2021.740057","volume":"12","author":"Q Jiang","year":"2021","unstructured":"Jiang Q, Li Z, Tao T, Duan R, Wang X, Su W (2021) TNF-\u03b1 in uveitis: from bench to clinic. Front Pharmacol 12:740057","journal-title":"Front Pharmacol"},{"key":"514_CR39","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ajo.2023.09.012","volume":"258","author":"F Pichi","year":"2024","unstructured":"Pichi F, Smith SD, Goldstein DA et al (2024) The Humira in Ocular inflammations Taper (HOT) study. Am J Ophthalmol 258:87\u201398","journal-title":"Am J Ophthalmol"},{"key":"514_CR40","doi-asserted-by":"crossref","unstructured":"Almoallim H, Al-Ghamdi Y, Almaghrabi H, Alyasi O (2012) Anti-tumor necrosis factor-\u03b1 induced systemic lupus erythematosus. Open Rheumatol J 6;315\u2013\u2009319","DOI":"10.2174\/1874312901206010315"},{"issue":"6","key":"514_CR41","doi-asserted-by":"publisher","first-page":"e558","DOI":"10.1212\/WNL.0000000000201472","volume":"100","author":"L Li","year":"2023","unstructured":"Li L, Avi\u00f1a-Zubieta JA, Bernstein CN et al (2023) Risk of multiple sclerosis among users of antitumor necrosis factor \u03b1 in 4 Canadian provinces: a population-based study. Neurology 100(6):e558\u2013e567","journal-title":"Neurology"},{"issue":"2","key":"514_CR42","doi-asserted-by":"publisher","first-page":"e000239","DOI":"10.1136\/rmdopen-2015-000239","volume":"2","author":"\u00c9 Toussirot","year":"2016","unstructured":"Toussirot \u00c9, Aubin F (2016) Paradoxical reactions under TNF-\u03b1 blocking agents and other biological agents given for chronic immune-mediated diseases: an analytical and comprehensive overview. RMD Open 2(2):e000239","journal-title":"RMD Open"},{"issue":"4","key":"514_CR43","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1007\/s00417-022-05862-9","volume":"261","author":"J-H Hung","year":"2023","unstructured":"Hung J-H, Rao NA, Chiu W-C, Sheu S-J (2023) Vitreoretinal surgery in the management of infectious and non-infectious uveitis \u2014 a narrative review. Graefes Arch Clin Exp Ophthalmol 261(4):913\u2013923","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"514_CR44","doi-asserted-by":"publisher","first-page":"755816","DOI":"10.3389\/fmed.2021.755816","volume":"8","author":"KW Kim","year":"2021","unstructured":"Kim KW, Kusuhara S, Imai H et al (2021) Outcomes of primary 27-gauge vitrectomy for 73 consecutive cases with uveitis-associated vitreoretinal disorders. Front Med (Lausanne) 8:755816","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"514_CR45","first-page":"509456","volume":"2015","author":"MR Abdulaal","year":"2015","unstructured":"Abdulaal MR, Abiad BH, Hamam RN (2015) Uveitis in the aging eye: incidence, patterns, and differential diagnosis. J Ophthalmol 2015(1):509456","journal-title":"J Ophthalmol"},{"issue":"5","key":"514_CR46","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s40266-018-0545-3","volume":"35","author":"E Akinsoji","year":"2018","unstructured":"Akinsoji E, Goldhardt R, Galor A (2018) A glimpse into uveitis in the aging eye: pathophysiology, clinical presentation and treatment considerations. Drugs Aging 35(5):399\u2013408","journal-title":"Drugs Aging"}],"container-title":["Journal of Ophthalmic Inflammation and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12348-025-00514-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12348-025-00514-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12348-025-00514-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T21:01:58Z","timestamp":1757278918000},"score":1,"resource":{"primary":{"URL":"https:\/\/joii-journal.springeropen.com\/articles\/10.1186\/s12348-025-00514-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,22]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["514"],"URL":"https:\/\/doi.org\/10.1186\/s12348-025-00514-5","relation":{},"ISSN":["1869-5760"],"issn-type":[{"value":"1869-5760","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,22]]},"assertion":[{"value":"24 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"As the JMDC database comprises de-identified data, informed consent is not required. The study was exempt from review by the Institutional Review Board of the Kobe University Graduate School of Medicine","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"S.Kusuhara: payment for lectures or supervision from AbbVie GK., AMO Japan K.K., Bayer Yakuhin, Ltd., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Company, Ltd., Eisai Co., Ltd., Kowa Company, Ltd., Mitsubishi Tanabe Pharma Corporation, Nippon Boehringer Ingelheim Co., Ltd., Nippon Kayaku, Novartis Pharma K.K., Santen Pharmaceutical Co., Ltd., Senju Pharmaceutical Co., Ltd., and Viatris Inc.; grants from AMO Japan K.K., Bayer Yakuhin, Ltd., and Chugai Pharmaceutical Co., Ltd.; receipt of drugs from Clinigen K.K.; patent royalties from Charmant, Inc.; K.Sonoda: financial support from AbbVie GK., Alcon Japan Ltd., Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., HOYA Corporation, Mitsubishi Tanabe Pharma Corporation, Otsuka Pharmaceutical Corporation, Santen Pharmaceutical Co., Ltd., Senju Pharmaceutical Co., Ltd., and Wakamoto Pharmaceutical Corporation; review panel member for Chugai Pharmaceutical Co., Ltd., Japan Tobacco Inc., Riverfield Corporation, Sand Corporation, Santen Pharmaceutical Co., Ltd., and Senju Pharmaceutical Co., Ltd.; T.K.: payment for lectures or supervision from AbbVie GK., Bayer Yakuhin, Ltd., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Company, Ltd., Eisai Co., Ltd., Kowa Company, Ltd., Mitsubishi Tanabe Pharma Corporation, Nippon Kayaku, Novartis Japan, Ono Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Santen Pharmaceutical Co., Ltd., and Senju Pharmaceutical Co., Ltd.; grants from AbbVie GK., Alcon Japan Ltd., Bayer Yakuhin, Ltd., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Company, Ltd., HOYA Corporation, Santen Pharmaceutical Co., Ltd., and Senju Pharmaceutical Co., Ltd.; receipt of drugs from Kowa Company, Ltd.; T.F., S.Katayama, M.M., T.N., M.N., T.O., Y.T., T.Y.: employees of Chugai Pharmaceutical Co., Ltd.; K.Sasaki, K.R.: employees of Datack, Inc., a paid vendor of Chugai Pharmaceutical Co., Ltd.; indirectly received consulting fees from Chugai Pharmaceutical Co., Ltd. through Datack, Inc.; K.Sato: employee of Third Place, LLC; received consulting fees from Datack, Inc.; H.G.: payment for lectures or supervision from AbbVie GK., Chugai Pharmaceutical Co., Ltd., Kowa Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Santen Pharmaceutical Co., Ltd., Senju Pharmaceutical Co., Ltd.; financial support from AbbVie GK., Alcon Japan Ltd., Chugai Pharmaceutical Co., Ltd., HOYA Corporation, Santen Pharmaceutical Co., Ltd., and Senju Pharmaceutical Co., Ltd.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"56"}}